From Oct. 15–Nov. 15, all donations to RheumPAC will be amplified by matching contributions, so it’s the best time to make your yearly investment. Donors above the silver level will be invited to a special event at ACR Convergence 2023.
The CMS Reveals First 10 Drugs for Medicare Drug Negotiation
The long-awaited list of the first 10 Part D drugs to be included in the new Medicare Price Negotiation process includes the commonly prescribed rheumatology drugs Enbrel and Stelara. Initial negotiations with the drug manufacturers will begin this fall.
ACR on the Hill: Members Ask Congress to Reduce Barriers to Care
In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.
FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
In Memoriam: Remembering Frederick Wolfe, MD
Rheumatology giant Frederick Wolfe, MD, passed away Sept. 5, 2023, in Wichita, Kan. The rheumatology community mourns his loss. Fred was born July 1, 1936, in New York. He graduated from Queens College, N.Y., in 1958, and was a social worker for several years. He earned his medical degree in 1966 from the State University…
Rheum for Everyone, Episode 1: Design Thinking & the Rheumatologist
In this premiere episode, Dr. Kumar discusses what’s new at The Rheumatologist, the deliberate approach we’ve taken to a redesign and how rheumatologists can incorporate human-centered design thinking into their practices.
Cannabis for Pain Relief: An Area Ripe for Research
Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.
Glucocorticoid Use at Any Dose Increases Fracture Risk
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
Findings from a Clinical Trial of Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue and pain than patients who received placebo.
The ACR Launches Rheumatoid Arthritis Measures Toolkit
The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 814
- Next Page »